Literature DB >> 7588990

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.

E Sam1, A P Jeanjean, J M Maloteaux, N Verbeke.   

Abstract

Apomorphine was administered subcutaneously and intranasally to 7 patients suffering from Parkinsonism with 'on-off' problems. This comparative pharmacokinetic study showed that the two routes of administration are comparable with respect to absorption kinetics. Apomorphine is rapidly absorbed when administered intranasally or subcutaneously with an absorption half life of 8.6 min and 5.8 min, respectively. The high rate of absorption is also reflected by the time for the plasma concentration to peak (tmax) and the lag times. The tmax was 23 min for intranasal route and 18 min for the subcutaneous route while the lag times were 2.8 min and 3.9 min, respectively. The bioavailability of intranasal apomorphine compared to the subcutaneous route amounted to 45%. After intranasal and subcutaneous administrations, the elimination half life of apomorphine amounted to 31 min and 27 min, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588990     DOI: 10.1007/BF03192285

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Rectal apomorphine: a new treatment modality in Parkinson's disease.

Authors:  T Van Laar; E N Jansen; A W Essink; W J Rutten; C Neef
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

2.  Intranasal apomorphine: a new treatment in Parkinson's disease.

Authors:  R Kapoor; N Turjanski; J Frankel; B Kleedorfer; A Lees; G Stern; M Bovingdon; R Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

3.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

4.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

5.  Apomorphine infusion for motor fluctuations in Parkinson's disease.

Authors:  J A Obeso; F Grandas; J Vaamonde; M Rosario Luguin; J M Martínez-Lage
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

6.  Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.

Authors:  C Stibe; A Lees; G Stern
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

7.  Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection.

Authors:  E Sam; P Augustijns; N Verbeke
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-19

8.  Determination of apomorphine in rat plasma and brain by high-performance liquid chromatography with electrochemical detection.

Authors:  G Bianchi; M Landi
Journal:  J Chromatogr       Date:  1985-02-27

9.  Peripheral pharmacokinetics of apomorphine in humans.

Authors:  S T Gancher; W R Woodward; B Boucher; J G Nutt
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

  9 in total
  6 in total

Review 1.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 2.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 3.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 4.  Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.

Authors:  Nrupa Borkar; Huiling Mu; René Holm
Journal:  Asian J Pharm Sci       Date:  2017-12-06       Impact factor: 6.598

5.  Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.

Authors:  L Iskhakova; P Rappel; M Deffains; G Fonar; O Marmor; R Paz; Z Israel; R Eitan; H Bergman
Journal:  Nat Commun       Date:  2021-12-02       Impact factor: 14.919

6.  S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis.

Authors:  Richard J Mead; Adrian Higginbottom; Scott P Allen; Janine Kirby; Ellen Bennett; Siân C Barber; Paul R Heath; Antonio Coluccia; Neelam Patel; Iain Gardner; Andrea Brancale; Andrew J Grierson; Pamela J Shaw
Journal:  Free Radic Biol Med       Date:  2013-04-19       Impact factor: 7.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.